Cannabidiol - MMJ PhytoTech

Drug Profile

Cannabidiol - MMJ PhytoTech

Alternative Names: PTL101

Latest Information Update: 28 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MMJ PhytoTech
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 26 Dec 2016 PhytoTech Therapeutics plans a phase II trial for Epilepsy in Israel (NCT02987114)
  • 31 Oct 2016 PhytoTech Therapeutics in-licenses Gelpell® product technology from Gelpell AG (MMJ PhytoTech's Annual report, October 2016)
  • 01 Mar 2016 PhytoTech Therapeutics completes a phase I trial in Epilepsy (In volunteers) in Israel (MMJ PhytoTech's Annual report, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top